NCT00131391终止3 期
A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 2,400
- 主要终点
- Decreases body weight; prevention of weight regain; safety and tolerability
研究概览
简要总结
A worldwide study in obese patients to assess the efficacy, safety, and tolerability of an investigational drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body Mass Index (BMI) between 30-43 kg/m2
排除标准
- •History of major psychiatric disorder
- •History of seizures or at high risk of developing seizures
- •Blood pressure greater than 160/100
- •Fasting blood glucose greater than 126 mg/dL
- •Triglycerides greater than 600 mg/dL
结局指标
主要结局
Decreases body weight; prevention of weight regain; safety and tolerability
时间窗: 2 Years
次要结局
- Decreases waist circumference, decreases the proportion of patients with metabolic syndrome, decreases triglycerides, decreases non-HDL-C, decreases LDL-C, decreases fasting insulin, decreases FPG; increases HDL-C, increases insulin sensitivity(2 Years)
研究者
相似试验
终止
3 期
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)ObesityNCT00131404Merck Sharp & Dohme LLC2,400
已完成
3 期
Obese Patients With Untreated DyslipidemiasObesityDyslipidemiaNCT00029835Sanofi1,033
已完成
3 期
Obese Patients With Type 2 DiabetesDiabetes Mellitus, Non-Insulin-DependentObesity in DiabetesObesityNCT00029848Sanofi1,045
终止
3 期
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And SafetyObesityNCT00375401Pfizer2,536
终止
3 期
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.ObesityNCT00396448Pfizer1,253